Study. Haematologica. 2010; 95:xxx doi:10.3324/haematol.2010 Grade 3/4 infections and gram-negative bacteremia were reduced in the pegylated liposomal doxorubicin arm (P = 0.04 and 0.02, respectively). There was a trend toward less cardiac events in patients receiving pegylated liposomal doxorubicin (1/29 versus 6/31). The complete remission rate was 82% and, with a median follow-up of 4 years, median event-free survival and overall survival were 9 and 10 months, respectively. Despite the better tolerance of pegylated liposomal doxorubicin, no differences in survivals were observed between both arms, due to trends towards more induction refractoriness (17 versus 3%, P = 0.10) and higher cumulative incidence of relapse (52 versus 32% at 2years, P = 0.20) in the pegylated liposomal doxorubicin arm.
INTRODUCTION
Data on older patients with acute lymphoblastic leukemia (ALL) are relatively scarce because of the low incidence of this disease among older adults. 1 The clinical benefit of intensive chemotherapy upon best supportive care has been established in this population. 2 However, the optimal chemotherapy remains to be determined. Published data, including 679 elderly patients from 19 studies, have been reviewed. 3 The complete remission (CR) rate was 59% (range 31-85), much lower than the 85-90% observed in younger adults. 3 This lower CR rate can be explained by both increased early mortality (23%, range 7.5-50) and increased induction failure (17%, range . Median overall survival ranging from 1 to 14 months and estimated 2-year overall survival (OS) ranging from 15 to 19% are largely inferior to those observed in younger adults. Age-adapted protocols, based on those used in younger adults but with some drugs being omitted or doses being reduced, decrease early mortality, 4 but OS remains poor.
New drugs or modalities of administration are therefore needed. The addition of anthracyclines in the vincristine-prednisone-Lasparaginase induction regimen increased the CR rate from 47 to 83% in adult ALL 5 but its tolerance in older patients is decreased. Continuous infusion (CI) may have enhanced therapeutic effects because of an enhanced efficacy and a decreased toxicity 6 . Anthracycline CI produced a more rapid cytoreduction than bolus infusion in ALL 12 without significant change in the drug's intracellular leukemic cells concentrations. 13 In the VAD regimen, developed at the MD Anderson, anthracycline CI seems to improve the survival of elderly ALL 7 and is nowadays considered as one of the reference treatments for this population. In this regimen, the absence of high doxorubicin peak plasma concentrations explains the relatively low incidence of side effects 8, 9 especially cardiomyopathy in patients with solid tumors 10 or multiple myeloma. 11 In ALL, cardiac dysfunction in children was reduced with CI doxorubicin (0/18 vs 4/18 after CI and bolus doxorubicin, respectively). 12 Encapsulation of anthracyclines in polyethylene-glycol liposomes might also increase their therapeutic effects. Pegylated liposomal doxorubicin (Peg-Dox) has several pharmacologic and safety advantages over conventional doxorubicin including 1) an extended circulation time with a half life of 55 hours, compared with 10 minutes for the free drug; 2) an increased extravasation through abnormal angiogenic vessels, thereby providing increased tumour exposure; and 3) a significantly lower risk of cardiotoxicity, gastrointestinal side effects, myelosuppression, and alopecia. [14] [15] [16] [17] To evaluate the respective value of Peg-dox and CI-doxorubicin (CI-Dox), we designed a randomized phase II trial comparing CI-Dox administered at 12 mg/m 2 /day during 4 days and Peg-Dox 40 mg/m 2 during first-line treatment in elderly patients with ALL. 
DESIGN AND METHODS

Patients
Treatments
Before randomization, patients received a 7-day pre-phase treatment with oral prednisone (40 mg/m 2 /d) and an intrathecal injection (IT) (Figure 1 followed by cranial irradiation, performed over a 2-week period prior to the onset of maintenance therapy. During maintenance, 6-mercaptopurine was discontinued for a week if white blood cell count (WBC) was < 2x10 9 /L, neutrophil count < 1x10 9 /L, and platelet count < 125x10 9 /L, respectively, doses of 6-mercaptopurine and methotrexate were increased by 25% if WBC was >3x10 9 /L. Patients with overt CNS involvement were given bi-weekly triple IT therapy until clearance of leukemic cells from the crerebral spinal fluid, followed by 6 triple IT therapies and CNS cranial irradiation. Central catheters were placed in all patients during the prednisone prephase. Anti-infectious prophylaxis was left to investigators' choice.
Statistical methods
The primary endpoint was designed as a composite efficacy/toxicity endpoint, including the rate of patients in continuous CR after day 140 to test for efficacy, and the request for having received at least the first three consolidation cycles without delay in schedule to test for toxicity. Secondary endpoints were CR rate, safety, cumulative incidence of relapse and failure, cumulative incidence of death in first CR and treatment-related death, event-free survival hazard ratio (HR) estimated by the Cox model. 21 By contrast, in estimating cumulative incidences we took into account competing risks using the cumulative incidence curves, then compared by the Gray test while the Fine and Gray model was used to estimate sub-distribution HR. 22, 23 The following covariates entered prognosis analysis: age (65 years cut-off) gender, Factors associated with a significant impact in univariate analysis were retained for multivariate logistic regression. Type 1 error was fixed at the 5% level. All tests were two-tailed. Statistical analysis was performed with Stata 10.0 software package (Texas union, TX, USA).
RESULTS
Patient characteristics
Thirty-one patients were randomized to receive CI-Dox and 29 patients to receive Peg-Dox ( 
Efficacy
After two induction courses, the overall CR rate was 82% (49 patients); 5 patients died during induction, all from invasive fungal infections (IFI) and 6 patients failed to achieve CR. Salvage therapy was left to investigators' decisions. One Peg-Dox failure was successfully rescued by administration of the CI-Dox regimen. The CR rate was lower in the Peg-Dox arm (72% versus 90%, P=0.10), due to a higher proportion of patients alive with refractory ALL after induction (17% versus 3%, P=0.10) ( Table 2 ). With respect to the primary endpoint, ie. the rate of patients alive in continuous CR after day 140 and having received at least the first three consolidation cycles, no difference was found between both randomization arms: 48% in the Peg-Dox arm (14 patients) versus 39% in the CI-Dox arm (12 patients) (P=0.60). At 2 years, the overall cumulative incidence of relapse was 41% (95%confidence interval, and death in first CR were higher in the CI-Dox arm, even if the differences were not statistically significant (P = 0.35 and 0.32, respectively) ( Table 2) . With a median follow-up of 4 years, median EFS and OS were 9 and 10 months, respectively, for the entire population. At 2 years, EFS and OS were estimated at 24% (95%confidence interval, Personal cancer histories present in 7 patients, were of no particular prognostic significance.
Safety
Main non-hematopoietic treatment-related adverse events are listed in Table 3 being lethal (5 patients). While gram-positive cocci bacteremia were equally distributed among both randomization groups, gram-negative bacteremia were mostly observed in the CI-Dox group, during both the induction (9 versus 1, P=0.02) and the consolidation phase (7 versus 2, P = 0.09) ( Table 3) .
Hematological toxicity was moderate and reduced in the Peg-Dox arm (Table 4) Overall, 5 patients died from induction toxicity (all from invasive fungal infection) and 13 patients died in first CR, including 11 deaths from post-CR treatment toxicity (1 patient in each arm later died from recurrence of a previous cancer). In the CI-Dox arm, 2 patients died from induction toxicity, and 8 patients died from post-CR treatment toxicity (including 5 infections).
In the Peg-Dox arm, 3 patients died from induction toxicity, and 3 patients died from post-CR treatment toxicity (including 2 infections).
DISCUSSION
The GRAALL-SA1 study is the largest randomised study ever published in this population of patients older than 60 with ALL. The few fully published studies with more patients consisted of reports of several different chemotherapy regimens. 4, 24 This emphasizes the difficulty in obtaining a significant improvement in this rare and very poor-risk population. In the GRAALL-SA1 study at the drug schedules used, Peg-Dox was associated with lower toxicity but did not improve survival due to higher induction failure and cumulative incidence of relapse.
In this population of elderly patients with ALL, liposomal encapsulation decreased doxorubicin's overall toxicity, especially in terms of myelosuppression, infection, and cardiotoxicity. The difference in the incidence of severe infection between both arms appeared to result from less toxicity in patients treated with Peg-Dox as the incidence in the CI-Dox arm was similar to previous reports. 10, 19, 20 The high incidence of gram-negative bacteriema observed after CI-Dox treatment is reminiscent of our previous results with daunorubicin CI in younger ALL patients. 25 This is likely related to the doxorubicin CI itself, rather than to the vincristine CI, as it was also observed during the consolidation phases that included standard 5-minutes vincristine infusion. The use of dexamethasone in both arms might also have increased the rate of infection, especially invasive fungal infection. 26 Studies evaluating systematic prophylaxis of gram-negative and fungal infection would be useful. Hematological toxicity was also significantly decreased after Peg-Dox for the three marrow lineages. Cardiac tolerance also seemed to be improved with Peg-Dox compared to CI-Dox. The prevalence of doxorubicinrelated cardiac complications is not specifically described in the literature for older patients, but chronic heart failure seems to occur more frequently and at lower cumulative doses. 27 Studies reported chronic heart failure occurrence after a cumulative doxorubicin dose < 200 mg/m 2 .
24,25
Finally, although not statistically significant, treatment-related mortality and post-remission treatment-related mortality were slightly reduced in the Peg-dox arm.
Despite reduced toxicity, the Peg-Dox regimen was not associated with improved survival. The CR rates observed, (90% with CI-Dox, 72% with Peg-Dox), were higher than previously reported 3 , with for instance only 58% CR ratse in the VAD study from the MDAC Center. 7 This might be related to the extensive use of G-CSF during the induction phase 28 and the absence of patients with Ph1-positive ALL in our study. In any case, more induction failures (17% versus 3%) and more relapses (52% versus 32%) were observed in the Peg-Dox arm with only 32% of patients being failure-free at 2 years versus 55% in the CI-Dox arm (P = 0.12).
The present 17% induction failure and 10% induction death in the Peg-Dox arm are not in line with results reported in a small study of liposomal daunorubicin in 15 patients, in whom the rate of patients alive in failure after induction was only 7%, with 20% induction deaths. 29 Overall, our results are disappointing. It may be due in part to the slight unbalance in favor of more T-ALL in the Peg-Dox arm, even if this feature had not been identified as a poor prognostic indicator in previous studies of patients with ALL older than 60 years of age. 1, 2, 4, 7, 24, 28, [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] Another explanation may be a wrong calculation of the Peg-Dox dose equivalence. As no pharmacokinetic studies were available comparing CI-Dox to Peg-Dox, the Peg-Dox dose was defined according to the pivotal randomized study in metastatic breast cancer 15 and studies performed in high-grade non-Hodgkin's lymphoma 41 , 42 that applied a 1.2 dose reduction factor between conventional doxorubicin and Peg-Dox, the total conventional doxorubicin dose being Although the major weakness of this study is the lack of sufficient power to detect small differences due to the rarity of the disease and low number of patients, the safety findings teach us many important things in investigating ALL in the elderly. Because CI-doxorubicin has not been unequivocally demonstrated to be better than standard doxorubicin, a randomized study between standard bolus doxorubicin versus CI-Dox versus Peg-Dox associated with pharmacokinetic studies should be encouraged probably in younger patients with clear stopping rules as there is a real possibility that Peg-Dox might be inferior to standard doxorubicin. CR: complete remission; EFS: event-free survival; OS: overall survival; *: primary endpoint; **: Cumulative Incidence of failure was estimated in the entire population including refractoriness to induction and relapse as events, while induction deaths and deaths in first CR accounted as competing events; ***: Cumulative Incidence of treatment-related death was estimated in the entire patient population including induction deaths and post-CR treatment-related deaths as events, while refractoriness to induction, relapses, or deaths unrelated to ALL therapy accounted as competing events. 
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